The global oncolytic virus market is expected to grow at a CAGR of 12.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of cancer and rising demand for novel therapies. The pharmaceutical segment is expected to dominate the global oncolytic virus market in terms of revenue, followed by health care and commercial segments. North America is expected to lead in terms of revenue share, followed by Europe and Asia Pacific respectively. -The global oncolytic virus market is expected to grow at a CAGR of 12.5% from 2018 to 2023. -The global oncolytic virus market is expected to reach USD 1,890 million by 2023 from USD 1,050 million in 2018. -Oncolytic viruses are being used as an alternative treatment for cancer and other diseases such as HIV and herpes simplex virus type 2 (HSV2). -Oncolytic viruses are also being used for the treatment of brain tumors, breast cancer, prostate cancer, cervical cancer and leukemia. -The use of oncolytic viruses has been approved by the FDA in the US for the treatment of brain tumors. -In addition to this, there are many clinical trials underway that will help increase awareness about this technology among physicians and patients alike.
Industry Growth Insights published a new data on “Oncolytic Virus Market”. The research report is titled “Oncolytic Virus Market research by Types (HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Vaccinia Virus-based Oncolytic Viruses, Vesicular Stomatitis Virus-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses), By Applications (Pharmaceutical, Health Care, Commerical), By Players/Companies Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux, Latima, Neotropix, Shanghai Sunway Biotech, SillaJen, Takara Bio, Theravir”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oncolytic Virus Market Research Report
By Type
HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Vaccinia Virus-based Oncolytic Viruses, Vesicular Stomatitis Virus-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses
By Application
Pharmaceutical, Health Care, Commerical
By Companies
Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux, Latima, Neotropix, Shanghai Sunway Biotech, SillaJen, Takara Bio, Theravir
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Oncolytic Virus Market Report Segments:
The global Oncolytic Virus market is segmented on the basis of:
Types
HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Vaccinia Virus-based Oncolytic Viruses, Vesicular Stomatitis Virus-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical, Health Care, Commerical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Otsuka Pharmaceutical Co
- Pfizer
- Roche
- Cold Genesys
- Genelux
- Latima
- Neotropix
- Shanghai Sunway Biotech
- SillaJen
- Takara Bio
- Theravir
Highlights of The Oncolytic Virus Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
- By Application:
- Pharmaceutical
- Health Care
- Commerical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oncolytic Virus Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oncolytic viruses are viruses that can kill cancer cells. They are often used in cancer treatments.
Some of the major companies in the oncolytic virus market are Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux, Latima, Neotropix, Shanghai Sunway Biotech, SillaJen, Takara Bio, Theravir.
The oncolytic virus market is expected to grow at a compound annual growth rate of 12.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oncolytic Virus Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oncolytic Virus Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oncolytic Virus Market - Supply Chain
4.5. Global Oncolytic Virus Market Forecast
4.5.1. Oncolytic Virus Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oncolytic Virus Market Size (000 Units) and Y-o-Y Growth
4.5.3. Oncolytic Virus Market Absolute $ Opportunity
5. Global Oncolytic Virus Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Oncolytic Virus Market Size and Volume Forecast by Type
5.3.1. HSV-based Oncolytic Viruses
5.3.2. Adenoviruses-based Oncolytic Viruses
5.3.3. Vaccinia Virus-based Oncolytic Viruses
5.3.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
5.3.5. Newcastle Disease Virus-based Oncolytic Viruses
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Oncolytic Virus Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Oncolytic Virus Market Size and Volume Forecast by Application
6.3.1. Pharmaceutical
6.3.2. Health Care
6.3.3. Commerical
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Oncolytic Virus Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Oncolytic Virus Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Oncolytic Virus Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Oncolytic Virus Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Oncolytic Virus Demand Share Forecast, 2019-2026
9. North America Oncolytic Virus Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Oncolytic Virus Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Oncolytic Virus Market Size and Volume Forecast by Application
9.4.1. Pharmaceutical
9.4.2. Health Care
9.4.3. Commerical
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Oncolytic Virus Market Size and Volume Forecast by Type
9.7.1. HSV-based Oncolytic Viruses
9.7.2. Adenoviruses-based Oncolytic Viruses
9.7.3. Vaccinia Virus-based Oncolytic Viruses
9.7.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
9.7.5. Newcastle Disease Virus-based Oncolytic Viruses
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Oncolytic Virus Demand Share Forecast, 2019-2026
10. Latin America Oncolytic Virus Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Oncolytic Virus Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Oncolytic Virus Market Size and Volume Forecast by Application
10.4.1. Pharmaceutical
10.4.2. Health Care
10.4.3. Commerical
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Oncolytic Virus Market Size and Volume Forecast by Type
10.7.1. HSV-based Oncolytic Viruses
10.7.2. Adenoviruses-based Oncolytic Viruses
10.7.3. Vaccinia Virus-based Oncolytic Viruses
10.7.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
10.7.5. Newcastle Disease Virus-based Oncolytic Viruses
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Oncolytic Virus Demand Share Forecast, 2019-2026
11. Europe Oncolytic Virus Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Oncolytic Virus Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Oncolytic Virus Market Size and Volume Forecast by Application
11.4.1. Pharmaceutical
11.4.2. Health Care
11.4.3. Commerical
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Oncolytic Virus Market Size and Volume Forecast by Type
11.7.1. HSV-based Oncolytic Viruses
11.7.2. Adenoviruses-based Oncolytic Viruses
11.7.3. Vaccinia Virus-based Oncolytic Viruses
11.7.4. Vesicular Stomatitis Virus-based Onolytic Viruses
11.7.5. Newcastle Disease Virus-based Oncolytic Viruses
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Oncolytic Virus Demand Share, 2019-2026
12. Asia Pacific Oncolytic Virus Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Oncolytic Virus Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Oncolytic Virus Market Size and Volume Forecast by Application
12.4.1. Pharmaceutical
12.4.2. Health Care
12.4.3. Commerical
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Oncolytic Virus Market Size and Volume Forecast by Type
12.7.1. HSV-based Oncolytic Viruses
12.7.2. Adenoviruses-based Oncolytic Viruses
12.7.3. Vaccinia Virus-based Oncolytic Viruses
12.7.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
12.7.5. Newcastle Disease Virus-based Oncolytic Viruses
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Oncolytic Virus Demand Share, 2019-2026
13. Middle East & Africa Oncolytic Virus Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Oncolytic Virus Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Oncolytic Virus Market Size and Volume Forecast by Application
13.4.1. Pharmaceutical
13.4.2. Health Care
13.4.3. Commerical
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Oncolytic Virus Market Size and Volume Forecast by Type
13.7.1. HSV-based Oncolytic Viruses
13.7.2. Adenoviruses-based Oncolytic Viruses
13.7.3. Vaccinia Virus-based Oncolytic Viruses
13.7.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
13.7.5. Newcastle Disease Virus-based Oncolytic Viruses
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Oncolytic Virus Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Oncolytic Virus Market: Market Share Analysis
14.2. Oncolytic Virus Distributors and Customers
14.3. Oncolytic Virus Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Otsuka Pharmaceutical Co
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cold Genesys
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Genelux
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Latima
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Neotropix
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Shanghai Sunway Biotech
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. SillaJen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Takara Bio
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Theravir
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook